Veltuzumab

N/A

Report date: 2023/05/05 17:38:42

Base Information

Drug NameVeltuzumab
Drug Alias Name维妥珠单抗hA20IMMU-106
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsPain, PostoperativePurpura, Thrombocytopenic, IdiopathicArthritis, Rheumatoid +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImmunomedics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGilead Sciences IncTakeda Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsPain, PostoperativePurpura, Thrombocytopenic, IdiopathicArthritis, Rheumatoid +[14] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG